Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 26, 1999

View Archived Issues

Company Profile: Alliance

Company Profile: Innogenetics

Genentech: Q4 and year-end 1998 highlights

Licensing opportunity from NIH: monomeric and dimeric arylisoquinoline alkaloids

Amide antibacterial agents with potential in gastric disorders in development at Mitsubishi

Novel antiallergic agents from Nissan act as both substance P and histamine antagonists

Hokuriku Seiyaku presents broad-spectrum antibacterial agents with good safety

Licensing opportunity from NIH: inhibitory and immunoblotting MAb specific for P-450 2A6

Hypoglycemic/hypoinsulinemic chromium complexes designed at Otsuka

Anti-H. pylori agents under investigation at Bayer

WHO maintains importance of male contraceptive research

Subunit-selective GABA-A receptor ligands for anxiety, convulsions reported by MS&D

More 5-HT4 receptor ligands in development at Synthelabo

New findings on the role of IFN-alpha in diabetes reported

Preclinical study results support development of antiulcer agent TU-199

Acupuncture and amitriptyline do not provide pain relief in HIV-related peripheral neuropathy

Trimeris to present preliminary phase II trial results of T-20

Synthelabo reports recent events in R&D

Japanese authorities approve Viagra

Deltagen to validate target genes for Roche Bioscience

Patent coverage sought by Viragen for second-generation interferon product

Studies in knockout mice support the role of CB1 receptor in opiate addiction

BTG enters agreement with Novo Nordisk for pain and epilepsy compounds

Iron chelator enhances ALA PDT efficacy in rat colon

Pharmadigm enters agreement with Mipharm for PB-005

Pharmacia & Upjohn's antiparkinsonian approved in Spain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...